Promoter methylation reduces C/EBPδ (CEBPD) gene expression in the SUM-52PE human breast cancer cell line and in primary breast tumors

Breast Cancer Research and Treatment

Volumn 95, Issue 2, 2006, Pages 161-170

  Tang, D ^a   Sivko, G S ^a   DeWille, J W ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Breast cancer; C EBP ; CCAAT Enhancer Binding Protein ; CEBPD; Epigenetic promoter methylation

Indexed keywords

AZACITIDINE; CCAAT ENHANCER BINDING PROTEIN DELTA; CYTOKINE; HISTONE H4; TRICHOSTATIN A;

ACETYLATION; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER CELL CULTURE; CHROMATIN; CONFORMATION; CONTROLLED STUDY; CPG ISLAND; EPIGENETICS; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BASE SEQUENCE; BREAST NEOPLASMS; CCAAT-ENHANCER-BINDING PROTEIN-DELTA; CHROMATIN IMMUNOPRECIPITATION; DNA METHYLATION; DOWN-REGULATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; G0 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 33645223741     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9061-3     Document Type: Article

References (48)

1. Ramji DP, Foka P: CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J 365: 561-575, 2002
2. Vinson C, Myakishev M, Acharya A, Mir A, Moll J, Bonowich M: Classification of human B-ZIP proteins based on dimerization properties. Mol Cell Biol 22: 6321-6335, 2002
3. Timchenko NA, Wilde M, Darlington GJ: C/EBPα regulates formation of S-Phase-Specific E2F-p107 complexes in livers of newborn mice. Mol Cell Biol 19: 2936-2945, 1999
4. Harris TE, Albrecht JH, Nakanishi M, Darlington GJ: CCAAT/Enhancer- binding Protein-α Cooperates with p21 to Inhibit Cyclin-dependent Kinase-2 Activity and Induces Growth Arrest Independent of DNA Binding. J Biol Chem 276: 29200-29209, 2001
5. Wang H, Iakova P, Wilde M, Welm A, Goode T, Roesler WJ, Timchenko NA: C/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4. Mol Cell 8: 817-828, 2001
6. Slomiany BA, D'Arigo KL, Kelly MM, Kurtz DT: C/EBPα inhibits cell growth via direct repression of E2F-DP-mediated transcription. Mol Cell Biol 20: 5986-5997, 2000
7. Wang H, Goode T, Iokova P, Albrecht JH, Timchenko NA: C/EBPα triggers proteasome-dependent degradation of cdk4 during growth arrest. EMBO J 21: 930-941, 2002
8. Chien P-L, Riley DJ, Chen-Kiang S, Lee W-H: Retinoblastoma protein directly interacts with and activates the transcription factor NF-IL6. Proc Nat Acad Sci 93: 465-469, 1996
9. D'Alo F, Johansen LM, Nelson EA, Radomska HS, Evans EK, Zhang P, Nerlov C, Tenen DG: The amino terminal and E2F interaction domains are critical for C/EBPα-mediated induction of granulopoietic development of hematopoietic cells. Blood 102: 3163-3171, 2003
10. Gery S, Gombart AF, Fung YK, Koeffler HP: C/EBPε interacts with retinoblastoma and E2F1 during granulopoiesis. Blood 103: 828-835, 2004
11. Ron D: TLS-CHOP and the role of RNA-binding proteins in oncogenic transformation. In: Rauscher FJ III, Vogt PK (eds) Chromosomal Translocations and Oncogenic Transcription factors. Springer-Verlag, Heidelberg, Germany 1997, pp 131-142
12. Tenen DG: Abnormalities of the CEBP alpha transcription factor: a major target in acute myeloid leukemia. Leukemia 15: 688-689, 2001
13. Halmos B, Huettner CS, Kocher O, Ferenczi K, Karp DD, Tenen DG: Down-regulation and antiproliferative role of C/EBPα in lung cancer. Cancer Res 62: 528-534, 2002
14. Zahnow CA: CCAAT/Enhancer binding protein in normal mammary development and breast cancer. Breast Cancer Res 4: 113-121, 2002
15. Porter D, Krop IE, Nasser S, Sgroi D, Kaelin C, Marks JR, Riggins G, Polyak KA: SAGE (Serial Analysis of Gene Expression) view of breast tumor progression. Cancer Res 61: 5697-5702, 2001
16. Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, Marks J, Richardson A, Cooper A, Strausberg R, Riggins GJ, Schnitt S, Gabrielson E, Gelman R, Polyak K: Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res 1: 362-375, 2003
17. Kuramoto T, Morimura K, Yamashita S, Okochi E, Watanabe N, Ohta T, Ohki M, Fukushima S, Sugimura T, Ushijima T: Etiology-specific gene expression profiles in rat mammary carcinomas. Cancer Res 62: 3592-3597, 2002
18. O'Rourke JP, Yuan R, DeWille JW: CCAAT/Enhancer binding protein-delta is induced in growth arrested mouse mammary epithelial cells. J Biol Chem 272: 6291-6296, 1997
19. 0 growth arrest and apoptosis. J Biol Chem 274: 16582-16589, 1999
20. 0 growth arrested mouse mammary epithelial cells. Biochem Biophys Res Comm 262: 696-701, 1999
21. Hutt JA, O'Rourke JP, DeWille JW: Stat3 activates C/EBPδ gene transcription in G0 growth arrested mouse mammary epithelial cells, in involuting mouse mammary gland. J Biol Chem 275: 29123-29131, 2000
22. Hutt JA, DeWille JW: Oncostatin M Induces growth arrest of mammary epithelial cells via a CCAAT/Enhancer binding protein delta dependent pathway. Mol Cancer Ther 1: 601-610, 2002
23. Sivko GS, DeWille JW: CCAAT/enhancer binding protein delta (C/EBPdelta) regulation and expression in human mammary epithelial cells: I. "Loss of function" alterations in the C/EBPdelta growth inhibitory pathway in breast cancer cell lines. J Cell Biochem 93: 830-843, 2004
24. Sivko GS, Sanford DC, Dearth LD, Tang D, DeWille JW: CCAAT/enhancer binding protein delta (C/EBPdelta) regulation and expression in human mammary epithelial cells: II. Analysis of activating signal transduction pathways, transcriptional, post-transcriptional, and post-translational control. J Cell Biochem 93: 844-856, 2004
25. Gigliotti AP, Johnson PJ, Sterneck E, DeWille JW: CCAAT/Enhancer Binding proteinδ (C/EBPδ) knockout mice exhibit increased mammary epithelial cell proliferation. Exp Biol Med 228: 278-285, 2003
26. Vegesan V, Takeuchi S, Hofmann W-K, Ikeezoe T, Tavor S, Krug U, Fermin AC, Heaney A, Miller CW, Koeffler HP: C/EBP-β, C/EBP-δ, PU.1, AML1 genes: mutational analysis in 381 samples of hematopietic and solid malignancies. Leukemia Res 26: 451-457, 2001
27. Tang D, DeWille JW: Detection of polymorphisms in the human C/EBPδ gene by single strand conformation polymorphism (SSCP) analysis. Mol Cellular Probes 17: 11-14, 2003
28. Nephew KP, Huang TH-M: Epigenetic gene silencing in cancer initiation and progression. Cancer Letts 190: 125-133, 2003
29. Widschwendter M, Jones PA: DNA methylation and breast carcinogenesis. Oncogene 21: 5462-5482, 2002
30. Zhu W-G, Srinivasan K, Dai Z, Duan W, Druhan LJ, Ding H, Yee L, Villalona-Calero A, Plass C, Otterson GA: Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21 cipl promoter. Mol Cell Biol 23: 4056-4065, 2003
31. Ethier SP, Kokeny EK, Ridings JW, Dilts A: erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line. Cancer Res 56: 899-907, 1996
32. Cantwell CA, Sterneck E, Johnson PF: Interleukin-6-specific activation of the C/EBPdelta gene in hepatocytes is mediated by Stat3 and Sp1. Mol Cell Biol 18: 2108-2117, 1998
33. Sanford DC, DeWille JW: C/EBPδ is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells. The Prostate 63: 143-154, 2005
34. Irvine RA, Lin IG, Hsieh C-L: DNA methylation has a local effect on transcription and histone acetylation. Mol Cell Biol 22: 6689-6696, 2002
35. Klochendler-Yeivin A, Yaniv M: Chromatin modifiers and tumor suppression. Biochim et Biophys Acta 1551: M1-M10, 2001
36. Peterson CL, Laniel MA: Histones and histone modifications. Current Biol 14: R546-551, 2004
37. Sherr CJ: Principles of tumor suppression. Cell 116: 235-246, 2004
38. Wood S, Schertzer M, Yaremko ML: Sequence identity locates CEBPD and FGFR1 to mapped human loci within proximal 8p. Cytogenet Cell Genet 70(3-4): 188-191, 1995
39. Nagaoka M, Shiraishi Y, Sugiura Y: Selected base sequence outside the target binding site of zinc finger protein Sp1. Nucl Acid Res 29: 4920-4929, 2001
40. Arapshian A, Kuppumbatti YS, Mira-y-Lopez R: Methylation of conserved CpG sites neighboring the beta retinoic acid response element may mediate retinoic acid receptor beta gene silencing in MCF-7 breast cancer cells. Oncogene 19: 4066-4070, 2000
41. Mancini DN, Rodenhiser DI, Ainsworth PJ, O'Malley FP, Singh SM, Xing W, Archer T: CpG methylation within the 5′ regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site. Oncogene 16: 1161-1169, 1998
42. Mancini-DiNardo DN, Butcher DT, Robinson DP, Archer TK, Rodenhiser DI: Functional analysis of CpG methylation in the BRCA1 promoter region. Oncogene 20: 5331-5340, 2001
43. Kerangueven F, Noguchi T, Coulier F, Allione F, Wargniez V, Simony-Lafontaine J, Longy M, Jacquemier J, Sobol H, Eisinger F, Birnbaum D: Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. Cancer Res 57: 5469-5474, 1997
44. Smiraglia DJ, Rush LJ, Fruhwald MC, Dai Z, Held WA, Costello JF, Lang JC, Eng C, Li B, Wright FA, Caligiuri MA, Plass C: Excessive CpG island hypermethylation in cancer cell lines versus primary malignancies. Hum Mol Genet 10: 1413-1419, 2001
45. Ueki T, Walter KM, Skinner H, Jaffee E, Hruban R, Goggins M: Aberrant CpG island methylation in cancer cell lines arises in the primary cancer from which they were derived. Oncogene 21: 2114-2117, 2002
46. Paz MF, Fraga MF, Avila S, Guo M, Pollan M, Herman JG, Estellar MA: Systematic profile of DNA methylation in human cancer cell lines. Cancer Res 63: 1114-1121, 2003
47. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botsein D, Brown PO, Weinstein JN: A gene expression database for the molecular pharmacology of cancer. Nature Genet 24: 236-244, 2000
48. Grant SL, Begley CG: The Oncostatin M signaling pathway, reversing the neoplastic phenotype. Mol Med Today 5: 406-412, 1999